JP4533391B2 - 中枢神経系疾患の処置のための５−ヒドロキシトリプタミンレセプター（５−ｈｔ）のモジュレーターとしての、１−ベンジル−５−ピペラジン−１−イル−３，４−ジヒドロ−１ｈ−キナゾリン−２−オン誘導体、ならびにそれぞれの１ｈ−ベンゾ（１，２，６）チアジアジン−２，２−ジオキシドおよび１，４−ジヒドロベンゾ（ｄ）（１，３）オキサジン−２−オン誘導体 - Google Patents
中枢神経系疾患の処置のための５−ヒドロキシトリプタミンレセプター（５−ｈｔ）のモジュレーターとしての、１−ベンジル−５−ピペラジン−１−イル−３，４−ジヒドロ−１ｈ−キナゾリン−２−オン誘導体、ならびにそれぞれの１ｈ−ベンゾ（１，２，６）チアジアジン−２，２−ジオキシドおよび１，４−ジヒドロベンゾ（ｄ）（１，３）オキサジン−２−オン誘導体 Download PDFInfo
- Publication number
- JP4533391B2 JP4533391B2 JP2006548231A JP2006548231A JP4533391B2 JP 4533391 B2 JP4533391 B2 JP 4533391B2 JP 2006548231 A JP2006548231 A JP 2006548231A JP 2006548231 A JP2006548231 A JP 2006548231A JP 4533391 B2 JP4533391 B2 JP 4533391B2
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- benzyl
- piperazin
- quinazolin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C)(C)OC(N(CC1)CCN1c1c(*)c(N=O)cc(OC)c1)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1c(*)c(N=O)cc(OC)c1)=O 0.000 description 1
- LSNDMCKIYVEPIE-UHFFFAOYSA-N COc(cc1[N+]([O-])=O)cc([N+]([O-])=O)c1C#N Chemical compound COc(cc1[N+]([O-])=O)cc([N+]([O-])=O)c1C#N LSNDMCKIYVEPIE-UHFFFAOYSA-N 0.000 description 1
- SNJNVLHIFSWKBF-UHFFFAOYSA-N N#Cc(c([N+]([O-])=O)cc(F)c1)c1[N+]([O-])=O Chemical compound N#Cc(c([N+]([O-])=O)cc(F)c1)c1[N+]([O-])=O SNJNVLHIFSWKBF-UHFFFAOYSA-N 0.000 description 1
- RFDRKSBHRPUUFM-UHFFFAOYSA-N N#Cc(c([N+]([O-])=O)cc(O)c1)c1[N+]([O-])=O Chemical compound N#Cc(c([N+]([O-])=O)cc(O)c1)c1[N+]([O-])=O RFDRKSBHRPUUFM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53708004P | 2004-01-16 | 2004-01-16 | |
| PCT/EP2005/000095 WO2005067933A1 (en) | 2004-01-16 | 2005-01-07 | 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(d) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007517826A JP2007517826A (ja) | 2007-07-05 |
| JP2007517826A5 JP2007517826A5 (https=) | 2008-08-28 |
| JP4533391B2 true JP4533391B2 (ja) | 2010-09-01 |
Family
ID=34794441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006548231A Expired - Fee Related JP4533391B2 (ja) | 2004-01-16 | 2005-01-07 | 中枢神経系疾患の処置のための５−ヒドロキシトリプタミンレセプター（５−ｈｔ）のモジュレーターとしての、１−ベンジル−５−ピペラジン−１−イル−３，４−ジヒドロ−１ｈ−キナゾリン−２−オン誘導体、ならびにそれぞれの１ｈ−ベンゾ（１，２，６）チアジアジン−２，２−ジオキシドおよび１，４−ジヒドロベンゾ（ｄ）（１，３）オキサジン−２−オン誘導体 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7196087B2 (https=) |
| EP (1) | EP1708713B1 (https=) |
| JP (1) | JP4533391B2 (https=) |
| KR (1) | KR100843053B1 (https=) |
| CN (1) | CN1909909B (https=) |
| AR (1) | AR047958A1 (https=) |
| AT (1) | ATE388712T1 (https=) |
| AU (1) | AU2005205016B2 (https=) |
| BR (1) | BRPI0506909A (https=) |
| CA (1) | CA2552681A1 (https=) |
| CO (1) | CO5700763A2 (https=) |
| DE (1) | DE602005005298T2 (https=) |
| ES (1) | ES2302174T3 (https=) |
| IL (1) | IL176631A0 (https=) |
| NO (1) | NO20062791L (https=) |
| RU (1) | RU2006129464A (https=) |
| TW (1) | TW200530222A (https=) |
| WO (1) | WO2005067933A1 (https=) |
| ZA (1) | ZA200605434B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008514663A (ja) * | 2004-09-30 | 2008-05-08 | エフ．ホフマン−ラ ロシュ アーゲー | 認知障害の処置用の組成物および方法 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| AU2005316739A1 (en) * | 2004-12-13 | 2006-06-22 | Galileo Pharmaceuticals, Inc. | Spiro derivatives as lipoxygenase inhibitors |
| BRPI0613430A2 (pt) * | 2005-07-13 | 2011-01-11 | Hoffmann La Roche | compostos derivados de benzimidazol, uso dos mesmos, método para a preparação destes e composição farmacêutica |
| KR100817538B1 (ko) * | 2006-07-05 | 2008-03-27 | 한국화학연구원 | 신규 치환된―１ｈ―퀴나졸린―２,４―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물 |
| CN101600698B (zh) * | 2006-09-11 | 2012-01-11 | 欧加农股份有限公司;药典有限责任公司 | 喹唑啉酮和异喹啉酮乙酰胺衍生物 |
| WO2008073958A2 (en) | 2006-12-12 | 2008-06-19 | Wyeth | Substituted benzothiadiazinedioxide derivatives and methods of their use |
| MX2010014394A (es) * | 2008-06-20 | 2011-05-19 | Rottapharm Spa | Derivados de 6-1h-imidazo-quinazolina y quinolinas, nuevos inhibidores de monoamina oxidasa y ligandos del receptor de imidazolina. |
| EP2328881A1 (en) * | 2008-09-08 | 2011-06-08 | F. Hoffmann-La Roche AG | 5-substituted benzoxazines |
| US20110288086A1 (en) | 2010-05-21 | 2011-11-24 | Jianqi Li | Polycyclic quinazolines, preparation thereof, and use thereof |
| IL309982A (en) * | 2016-11-15 | 2024-03-01 | Univ Temple | New modulators of 5-hydroxytryptamine receptor 7 and a method of using them |
| MX2021013135A (es) | 2019-04-29 | 2021-11-25 | Solent Therapeutics Llc | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2. |
| JP7696354B2 (ja) * | 2019-10-21 | 2025-06-20 | アライリオン インコーポレイテッド | 睡眠障害の治療のためのＨ１および５－ＨＴ２Ａ受容体調節物質としての３－（４－（１１Ｈ－ジベンゾ［ｂ，ｅ］［１，４］アゼピン－６－イル）ピペラジン－１－イル）－プロパン酸誘導体および３－（４－（ジベンゾ［ｂ，ｆ］［１，４］オキサゼピン／チアゼピン／ジアゼピン－１１－イル）ピペラジン－１－イル）－プロパン酸誘導体 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3642791A (en) | 1969-08-13 | 1972-02-15 | Sandoz Ag | Morpholino-1-substituted-2(1h)-quinazolinones |
| JPS5271483A (en) | 1975-12-11 | 1977-06-14 | Sumitomo Chem Co Ltd | Synthesis of 2(1h)-quinazolinone derivatives |
| CN1015459B (zh) * | 1985-06-06 | 1992-02-12 | 田边制药株式会社 | 喹唑啉酮化合物的制备方法 |
| GR1000821B (el) * | 1988-11-22 | 1993-01-25 | Tanabe Seiyaku Co | Μεθοδος παραγωγης παραγωγων κιναζολινονης. |
| WO1998018781A2 (en) | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents |
| AU6423298A (en) | 1997-03-26 | 1998-10-20 | Sumitomo Pharmaceuticals Company, Limited | 4-arylmethylene-1,4-dihydro-2h-azine derivatives |
| DK1028950T3 (da) | 1997-10-28 | 2003-09-01 | Warner Lambert Co | 7-substituerede quinazolin-2,4-dioner nyttige som antibakterielle midler |
| WO1999037643A1 (en) * | 1998-01-26 | 1999-07-29 | Yamanouchi Pharmaceutical Co., Ltd. | Novel benzene-fused heterocyclic derivatives or salts thereof |
| JP2003513075A (ja) * | 1999-11-05 | 2003-04-08 | スミスクライン ビーチャム パブリック リミテッド カンパニー | 複合５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体活性を有するイソキノリンおよびキナゾリン誘導体 |
| AU1626001A (en) | 1999-11-23 | 2001-06-04 | Smithkline Beecham Corporation | 3,4-dihydro-(1h)-quinazolin-2-ones and their use as csbp/p38 kinase inhibitors |
| WO2001044228A2 (fr) | 1999-12-14 | 2001-06-21 | Sanofi-Synthelabo | Derives de quinazolinedione et phtalimide, leurs preparations et leurs applications en therapeutique |
| JP2004521892A (ja) * | 2000-12-20 | 2004-07-22 | メルク エンド カムパニー インコーポレーテッド | （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤 |
| US6998408B2 (en) | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
| ES2268113T3 (es) * | 2001-06-15 | 2007-03-16 | F. Hoffmann-La Roche Ag | Derivados de 4-piperazinilindol con afinidad al receptor 5-ht6. |
| GB0203804D0 (en) * | 2002-02-18 | 2002-04-03 | Glaxo Group Ltd | Compounds |
| PT1506179E (pt) * | 2002-05-13 | 2006-06-30 | Hoffmann La Roche | Derivados de benzoxazina como moduladores de 5-ht6 e suas utilizacoes |
-
2005
- 2005-01-07 JP JP2006548231A patent/JP4533391B2/ja not_active Expired - Fee Related
- 2005-01-07 RU RU2006129464/04A patent/RU2006129464A/ru unknown
- 2005-01-07 KR KR1020067014320A patent/KR100843053B1/ko not_active Expired - Fee Related
- 2005-01-07 DE DE602005005298T patent/DE602005005298T2/de not_active Expired - Lifetime
- 2005-01-07 BR BRPI0506909-2A patent/BRPI0506909A/pt not_active IP Right Cessation
- 2005-01-07 EP EP05700747A patent/EP1708713B1/en not_active Expired - Lifetime
- 2005-01-07 ES ES05700747T patent/ES2302174T3/es not_active Expired - Lifetime
- 2005-01-07 CN CN2005800026123A patent/CN1909909B/zh not_active Expired - Fee Related
- 2005-01-07 WO PCT/EP2005/000095 patent/WO2005067933A1/en not_active Ceased
- 2005-01-07 CA CA002552681A patent/CA2552681A1/en not_active Abandoned
- 2005-01-07 AT AT05700747T patent/ATE388712T1/de active
- 2005-01-07 AU AU2005205016A patent/AU2005205016B2/en not_active Ceased
- 2005-01-13 AR ARP050100106A patent/AR047958A1/es not_active Application Discontinuation
- 2005-01-13 TW TW094101029A patent/TW200530222A/zh unknown
- 2005-01-14 US US11/035,506 patent/US7196087B2/en not_active Expired - Fee Related
-
2006
- 2006-06-15 NO NO20062791A patent/NO20062791L/no not_active Application Discontinuation
- 2006-06-29 IL IL176631A patent/IL176631A0/en unknown
- 2006-06-30 ZA ZA200605434A patent/ZA200605434B/en unknown
- 2006-07-13 CO CO06068258A patent/CO5700763A2/es not_active Application Discontinuation
-
2007
- 2007-02-07 US US11/703,424 patent/US7365063B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008514663A (ja) * | 2004-09-30 | 2008-05-08 | エフ．ホフマン−ラ ロシュ アーゲー | 認知障害の処置用の組成物および方法 |
| JP2011157394A (ja) * | 2004-09-30 | 2011-08-18 | F Hoffmann La Roche Ag | 認知障害の処置用の組成物および方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005067933A1 (en) | 2005-07-28 |
| TW200530222A (en) | 2005-09-16 |
| US7365063B2 (en) | 2008-04-29 |
| NO20062791L (no) | 2006-08-01 |
| JP2007517826A (ja) | 2007-07-05 |
| KR100843053B1 (ko) | 2008-07-01 |
| CA2552681A1 (en) | 2005-07-28 |
| EP1708713A1 (en) | 2006-10-11 |
| ATE388712T1 (de) | 2008-03-15 |
| DE602005005298T2 (de) | 2009-03-12 |
| AR047958A1 (es) | 2006-03-15 |
| US20050165001A1 (en) | 2005-07-28 |
| AU2005205016A1 (en) | 2005-07-28 |
| CO5700763A2 (es) | 2006-11-30 |
| ES2302174T3 (es) | 2008-07-01 |
| RU2006129464A (ru) | 2008-02-27 |
| KR20060126720A (ko) | 2006-12-08 |
| CN1909909A (zh) | 2007-02-07 |
| ZA200605434B (en) | 2008-02-27 |
| IL176631A0 (en) | 2006-10-31 |
| EP1708713B1 (en) | 2008-03-12 |
| US20070149510A1 (en) | 2007-06-28 |
| AU2005205016B2 (en) | 2010-07-15 |
| CN1909909B (zh) | 2010-12-15 |
| BRPI0506909A (pt) | 2007-05-29 |
| US7196087B2 (en) | 2007-03-27 |
| DE602005005298D1 (de) | 2008-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7365063B2 (en) | Quinazolinone and benzoxazinone derivatives and uses thereof | |
| JP4401297B2 (ja) | 置換ベンゾオキサジノン及びその使用 | |
| JP4527730B2 (ja) | ベンゾオキサジン誘導体及びその使用 | |
| JP4404893B2 (ja) | キノリノン／ベンゾオキサジノン誘導体及びそれらの使用 | |
| JP4738418B2 (ja) | クロマン誘導体及びｃｎｓ障害の処置におけるその使用 | |
| JP2008514662A (ja) | ベンゾオキサジン及びキノキサリン誘導体並びに使用 | |
| MXPA06007907A (en) | 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(d) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system | |
| HK1087114B (en) | Substituted benzoxazinones and uses thereof | |
| HK1087114A1 (zh) | 取代的苯并恶嗪酮及其用途 | |
| MXPA06005840A (en) | Benzoxazine derivatives and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080610 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100126 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100525 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100611 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130618 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |